Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)LeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares Repurchased
Ratios

Amphastar Pharmaceuticals (AMPH) Leases (2016 - 2025)

Amphastar Pharmaceuticals has reported Leases over the past 13 years, most recently at $42.9 million for Q4 2025.

  • Quarterly results put Leases at $42.9 million for Q4 2025, down 8.46% from a year ago — trailing twelve months through Dec 2025 was $42.9 million (down 8.46% YoY), and the annual figure for FY2025 was $42.9 million, down 8.46%.
  • Leases for Q4 2025 was $42.9 million at Amphastar Pharmaceuticals, up from $259000.0 in the prior quarter.
  • Over the last five years, Leases for AMPH hit a ceiling of $46.9 million in Q4 2024 and a floor of $201000.0 in Q2 2022.
  • Median Leases over the past 5 years was $13.5 million (2022), compared with a mean of $17.4 million.
  • Biggest five-year swings in Leases: skyrocketed 12998.01% in 2023 and later tumbled 99.18% in 2025.
  • Amphastar Pharmaceuticals' Leases stood at $353000.0 in 2021, then soared by 113.31% to $753000.0 in 2022, then dropped by 25.1% to $564000.0 in 2023, then surged by 8215.43% to $46.9 million in 2024, then decreased by 8.46% to $42.9 million in 2025.
  • The last three reported values for Leases were $42.9 million (Q4 2025), $259000.0 (Q3 2025), and $44.2 million (Q2 2025) per Business Quant data.